DermTech (NASDAQ:DMTK) and CBA Florida (OTCMKTS:CBAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Risk & Volatility

DermTech has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, CBA Florida has a beta of -0.25, meaning that its stock price is 125% less volatile than the S&P 500.

Institutional & Insider Ownership

33.4% of DermTech shares are held by institutional investors. 21.0% of DermTech shares are held by company insiders. Comparatively, 30.0% of CBA Florida shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares DermTech and CBA Florida’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
DermTech N/A N/A $940,000.00 N/A N/A
CBA Florida N/A N/A $13.17 million N/A N/A

Analyst Recommendations

This is a summary of recent ratings and recommmendations for DermTech and CBA Florida, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
DermTech 0 0 1 0 3.00
CBA Florida 0 0 0 0 N/A

DermTech currently has a consensus target price of $15.00, suggesting a potential upside of 8.54%. Given DermTech’s higher possible upside, analysts plainly believe DermTech is more favorable than CBA Florida.


This table compares DermTech and CBA Florida’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
DermTech N/A -50.28% -23.12%
CBA Florida N/A -14.89% -14.01%

About DermTech

DermTech, Inc., a molecular genomics company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company sells its products to pathology and oncology practitioners. DermTech, Inc. was incorporated in 1995 and is headquartered in La Jolla, California.

About CBA Florida

CBA Florida, Inc. does not have significant operations. Previously, the company provided private cord blood and cord tissue stem cell services. The company was formerly known as Cord Blood America, Inc. and changed its name to CBA Florida, Inc. in May 2018. CBA Florida, Inc. is based in Las Vegas, Nevada.

Receive News & Ratings for DermTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DermTech and related companies with's FREE daily email newsletter.